Background and objective Several studies have found that chronic treatment with the dietary flavonoid quercetin lowers blood pressure and restores endothelial dysfunction in hypertensive animal models. We hypothesized that increased endothelial nitric oxide synthase (eNOS) and/or decreased nicotinamide adenine dinucleotide phosphate (NADPH) oxidase protein expression and activity, and reduced reactive oxygen species might be involved in the improvement of endothelial function induced by quercetin in sponataneously hypertensive rats (SHR). Results In SHR, quercetin reduced the increase in blood pressure and heart rate and enhanced the endotheliumdependent aortic vasodilation induced by acetylcholine, but had no effect on the endothelium-independent response induced by nitroprusside. However, quercetin had no effect on endothelium-dependent vasoconstriction and aortic thromboxane B 2 production. Compared to WKY, SHR showed upregulated eNOS and p47 phox protein expression, downregulated caveolin-1 expression, increased NADPH-induced superoxide production but, paradoxically, eNOS activity was reduced. Chronic quercetin treatment prevented all these changes in SHR. In WKY, quercetin had no effect on blood pressure, endothelial function or the expression or activity of the proteins analysed.
Results In SHR, quercetin reduced the increase in blood pressure and heart rate and enhanced the endotheliumdependent aortic vasodilation induced by acetylcholine, but had no effect on the endothelium-independent response induced by nitroprusside. However, quercetin had no effect on endothelium-dependent vasoconstriction and aortic thromboxane B 2 production. Compared to WKY, SHR showed upregulated eNOS and p47 phox protein expression, downregulated caveolin-1 expression, increased NADPH-induced superoxide production but, paradoxically, eNOS activity was reduced. Chronic quercetin treatment prevented all these changes in SHR. In WKY, quercetin had no effect on blood pressure, endothelial function or the expression or activity of the proteins analysed.
Introduction
Flavonoids comprise a large group of polyphenolic compounds widely distributed in plants and present in variable amounts in dietary vegetables and fruit [1] . The estimated average human daily intake of flavonoids is 22-23 mg (flavonols plus flavones), of which quercetin represents about 60-75% [2] . The meta-analysis of seven prospective cohort studies on dietary flavonoid intake concluded that the individuals in the top third of dietary flavonol intake are associated with a reduced risk of mortality from coronary heart disease as compared with those in the bottom third, after adjustment for known risk factors and other dietary components [3] . A very wide range of biological actions of flavonoids, including antioxidant, antiaggregant and vasodilator effects [1, 4] are consistent with these protective effects of quercetin in cardiovascular diseases. Several studies have found that chronic quercetin lowered blood pressure in hypertensive animal models such as the spontaneously hypertensive rat (SHR) [5] , nitric oxide (NO) deficient rats (chronically treated with N v -nitro-L-arginine methyl ester; L-NAME) [6] , deoxycorticosterone-salt hypertensive rats [7] , Dahl salt-sensitive hypertensive rats [8] and two-kidney, oneclip Goldblatt hypertensive rats [9] . These effects were associated with a reduction in plasma and urine markers of oxidative status, cardiac hypertrophy, renal damage and improved endothelial function.
Endothelial dysfunction, characterized by impaired endothelium-dependent vasodilation and a prothrombotic and proinflammatory state of endothelial cells, is an early and independent predictor of poor prognosis in most forms of cardiovascular disease [10] , including essential hypertension [11] . The most characteristic pathophysiological feature of endothelial dysfunction is a diminished bioactivity of endothelium-derived NO due to reduced endothelial NO synthase (eNOS) activity and/ or increased metabolism through its interaction with superoxide anion (O 2 À ) produced in the vascular wall by free-radical-generating enzymes, such as nicotinamide adenine dinucleotide phosphate (NADPH) oxidase [12] .
Therefore, the aim of the present study was to analyse the mechanisms involved in the improvement of endothelial function in SHR after chronic administration of an oral daily dose of quercetin (10 mg/kg). This dose of quercetin was chosen based on the highest tertile/quartile of human intake in the diet [2] , corrected by interspecies scaling principles [13] . We hypothesized that increased eNOS and/or decreased NADPH oxidase protein expression and activity and reduced reactive oxygen species might be involved in the improvement of endothelial function induced by quercetin in SHR. Wistar-Kyoto rats (WKY) were used as normotensive controls.
Methods

Animals and experimental protocol
Five-week-old, male SHR and WKY rats were obtained from Harlan Laboratories (Barcelona, Spain). All rats were maintained, five per cage, at a constant temperature (24 AE 18C), with a 12-h dark/light cycle and on standard rat chow. Twenty WKY and 18 SHR were randomly assigned to a control group (vehicle, 1 ml of 1% methylcellulose) or a quercetin group (10 mg/kg, mixed in 1 ml of 1% methylcellulose). Rats were weighed weekly and the dose adjusted accordingly. Drugs were given by gavage daily for 13 weeks. During the experimental period rats had free access to tap water and chow. Body weight was measured every week. The quercetin treatment was stopped 2 days before the end of the experiment, in order to study the long-term effects of quercetin without the involvement of the effects of acute administration. Four control and four quercetin-treated WKY and SHR were used at the end of the study for direct blood pressure measurements, and the remaining animals in each group were used for the analysis of vascular function. All the experiments were performed in accordance with institutional guidelines for the ethical care of animals.
Blood pressure measurements Systolic blood pressure (SBP) was measured weekly 18-20 h after administration of the drugs in conscious, prewarmed, restrained rats by tail-cuff plethysmography [5] . At least seven determinations were made in every session, and the mean of the lowest three values within 5 mmHg was taken as the systolic blood pressure level. At the end of week 13, direct blood pressure was measured in conscious WKY and SHR. For this purpose, the rats were anaesthetized with 2.5 ml/kg equitensin. A polyethylene catheter (PE-50) containing 100 U heparin in isotonic, sterile NaCl solution was inserted into the right femoral artery for intra-arterial blood pressure and heart rate measurement in conscious rats. The catheter was tunnelled subcutaneously, exteriorized through the skin on the dorsal side of the neck, and protected with a silver spring. Rats were allowed to recover for 24 h and, after connecting the catheter to a transducer and a two-channel recorder (TRA-021 and Letigraph 2000, respectively; Letica SA, Barcelona, Spain), blood pressure and heart rate were recorded continuously for 60 min.
Cardiac and renal morphology
The heart and kidneys were excised, cleaned and weighed. The atria and the right ventricle were then removed and the remaining tissue (left ventricle plus septum) weighed. The heart weight index (HW/BW), the left ventricular weight index (LVW/BW) and the kidney weight index (KW/BW) were calculated by dividing the heart weight (HW), the left ventricular weight (LVW) and the kidney weight (KW), respectively, by the body weight (BW). Rings were stretched to 2 g of resting tension by means of two L-shaped stainless-steel wires inserted into the lumen and attached to the chamber and to an isometric force-displacement transducer (Letigraph 2000), respectively, as described previously [5] . The concentration-relaxation response curves to acetylcholine (10 À8
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À5 mol/l) were performed in rings pre-contracted by 10 À7 mol/l phenylephrine. The concentration-relaxation response curves to nitroprusside (10 À10 -10 À5 mol/l) were performed in the dark in rings pre-contracted by 10 À6 mol/l noradrenaline. Endothelium-dependent contractions to acetylcholine were tested in rings which were initially stimulated with 80 mmol/l KCl. After washing in Krebs solution and incubation for 30 min with L-NAME (10 À4 mol/l), acetylcholine was added in a cumulative fashion (10 À8 -10 À4 mol/l). In these experiments, the contractile responses to acetylcholine were expressed as a percentage of the response to KCl. 
Measurement of vascular NOS activity
Determination of vascular thromboxane B 2 production
To determine the production of thromboxane B 2 (TXB 2 ), endothelium-intact aortic rings from different experimental groups were placed in 2 ml of Krebs solution bubbled with 95% O 2 and 5% CO 2 gas mixture and kept at 378C in the presence of L-NAME (10 À4 mol/l) for 15 min. At the end of this period, 500 ml of the medium was collected and TXB 2 was measured by an enzyme immunoassay (Amersham Life Science, Buckinghamshire, UK).
Detection of vascular O 2
S production O 2 À production in intact aortic segments was quantified by lucigenin-enhanced chemiluminescence, as previously described by Ohara et al. [14] . Aortic rings from all experimental groups were incubated for 30 min at 378C in HEPES-containing physiological salt solution (pH 7.4) of the following composition (in mmol/l): NaCl, 119; HEPES, 20; KCl, 4.6; MgSO 4 , 1; Na 2 HPO 4 , 0.15; KH 2 PO 4 , 0.4; NaHCO 3 , 1; CaCl 2 , 1.2; and glucose, 5.5. Aortic production of O 2 À was stimulated by addition of NADPH (100 mmol/l). Rings were then placed in tubes containing physiological salt solution, with or without NADPH, and lucigenin was injected automatically at a final concentration of 5 mmol/l. Changes in O 2 À release were determined by measuring luminescence over 200 s in a scintillation counter (Lumat LB 9507; Berthold, Germany) in 5-s intervals. Vessels were then dried, and dry weight was determined. O 2 À release is expressed as relative luminescence units (RLU)/min per mg dry aortic tissue. (8, 15 or 10%, respectively) electrophoresis was performed in a mini-gel system (Bio-Rad Laboratories, Hercules, California, USA). The proteins were transferred to polyvinylidene difluoride membranes (PVDF) overnight and incubated with primary polyclonal antibodies for eNOS (1 : 1000 dilution; Transduction Laboratories, San Diego, California, USA), p47 phox (1 : 1000 dilution; SantaCruz Biotechnology, Santa Cruz, California, USA), and monoclonal antibody for caveolin-1 (1 : 600 dilution; Transduction Laboratories). The membranes were then washed five times for 10 min each, in Tris-buffered saline-0.1% Tween 20 (TBST) and incubated with secondary peroxidase-conjugated goat antirabbit antibody (1 : 2000; Santa Cruz Biotechnology) for eNOS and p47 phox , and goat antimouse antibody (1 : 2000; Santa Cruz Biotechnology) in 5% non-fat dry milk-TBST. All incubations were performed at room temperature for 2 h. After washing the membranes, antibody binding was detected by an ECL system (Amersham Pharmacia Biotech, Amersham, Buckinghamshire, UK). Films were scanned and densitometric analysis was performed on the scanned images using Scion Image-Release Beta 4.02 software (http:// www.scioncorp.com). Results were expressed as the percentage of protein staining versus basal expression in aortas from the WKY control group.
Statistical analysis
Results are expressed as means AE SE means of measurements. The evolution of tail SBP with time was compared using the nested design, with treatment and days as fixed factors and the rat as a random factor. When the overall difference was significant, comparisons were made using Bonferroni's method with an appropriate error. Analysis of the nested design was also carried out with groups and concentrations to compare the concentration-response curves to acetylcholine. The remaining variables were compared using a two-way factor design, where group and treatment were fixed effect factors with unequal sample sizes in the different groups. When an interaction was significant, Bonferroni's method was used for pairwise comparisons. P < 0.05 was considered statistically significant. Concentration-response curves were fitted to the logistic equation:
, where E max is the maximal effect, k is a factor that represents the slope of the curve, and pD 2 is the drug concentration exhibiting 50% of the E max expressed as negative log molar.
Results
Blood pressure and heart rate Figure 1 shows the time course of the effects of quercetin on tail SBP and direct measurements of the mean arterial pressure (MAP) and heart rate (HR) at the end of the treatment period. Long-term quercetin administration reduced the increase in SBP in SHR, and this effect reached statistical significance after the fifth week of treatment, while no changes were observed in WKY rats (Fig. 1a) . At the end of the 13 weeks of treatment, direct measurements of blood pressure in conscious rats showed that quercetin induced a significant reduction in mean arterial pressure (À12%) and heart rate in SHR but not in WKY (Fig. 1b, c) .
Morphological variables
Treatment with quercetin did not modify the body weight in either SHR or WKY rats. The heart weight index (HW/BW) and left ventricular weight index (LVW/ BW) in SHR were significantly greater than in WKY. LVW/BW was significantly reduced in quercetin-treated SHR as compared to vehicle-treated SHR ( Table 1) .
Effects of quercetin on vasodilator responses in thoracic aorta
Aortas from vehicle-treated SHR showed significantly reduced endothelium-dependent vasodilator responses to acetylcholine in arteries stimulated by phenylephrine, as compared to aortas from control WKY (Fig. 2a) . However, no differences were observed in the endotheliumindependent vasodilator responses to the NO donor sodium nitroprusside (SNP) in vessels pre-contracted with noradrenaline (Fig. 2b) . Quercetin produced a significant increase in the relaxation induced by 10 À7 and 10 À6 mol/l acetylcholine in SHR, being without effect in WKY rats (Fig. 2a) . However, quercetin did not modify the relaxant responses to sodium nitroprusside (Fig. 2b) . Figure 2c shows that the NADPH oxidase inhibitor apocynin (10 À3 mol/l) added to the bath significantly enhanced acetylcholine-induced relaxation in rings from untreated SHR, but not from WKY.
Effects of quercetin on endotheliumdependent vasoconstriction
In the presence of L-NAME (10 À4 mol/l), aortas from SHR showed increased endothelium-dependent vasoconstrictor responses to acetylcholine when compared to their normotensive WKY counterparts (Fig. 3) . Coincubation of the vessels with SQ-29,548 (10 À7 mol/l), an antagonist of prostanoid thromboxane-endoperoxide receptors, almost abolished these contractions, suggesting that they are mediated by the release of a vasoconstrictor prostanoid. However, quercetin treatment had no effect on endothelium-dependent vasoconstriction induced by acetylcholine (Fig. 3 ).
Thromboxane B 2 production in thoracic aorta TXB 2 is the stable metabolite of the vasoconstrictor and platelet pro-aggregant prostanoid TXA 2 and, thus, TXB 2 production was used to estimate TXA 2 synthesis. TXB 2 production was significantly higher in the incubation media of aortic rings from SHR as compared to those from WKY (Fig. 4) . However, quercetin treatment was without effect on TXB 2 production in both strains.
Effects of quercetin on vascular eNOS activity, and eNOS and caveolin-1 protein expression
Compared with the WKY control group, untreated SHR exhibited a significant reduction of aortic eNOS activity (Fig. 5a) . Paradoxically, protein expression of eNOS was higher and caveolin-1 was lower in the aortas of SHR than in the corresponding WKY group (Fig. 5b) . After treatment of SHR with quercetin for 13 weeks, eNOS activity was increased, while eNOS and caveolin-1 protein expression was reduced and increased, respectively. Therefore, eNOS activity and eNOS and caveolin-1 expression in aortas from quercetin-treated SHR were similar to those from normotensive WKY.
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Effects of quercetin on vascular production of O 2
S and p47 phox expression No significant differences were found in basal vascular production of O 2 À within groups, as measured by the chemiluminescence of lucigenin (Fig. 6a) . Aortic incubation with 100 mmol/l NADPH enhanced O 2 À in both strains, but the increase was significantly higher in SHR than WKY control rats. In a set of experiments of untreated SHR and WKY of similar age, pre-incubation of vessel segments with superoxide dismutase (SOD, 150 U/ml) decreased the lucigenin chemiluminescence signals to background levels, and the inhibitor of NADPH oxidase, diphenyleneiodonium (10 mmol/l), suppressed the increase induced by NADPH (data not shown). Chronic treatment with quercetin induced a significant decrease of NADPH-stimulated O 2 À production only in SHR, being without effect in WKY rats.
Overexpression of membrane NADPH-oxidase components has been associated with enhanced O 2 À generation in certain pathophysiological conditions [15] [16] [17] . We studied the protein expression of p47 phox , a subunit of NADPH oxidase which is known to be upregulated in hypertension. As expected, in untreated SHR aortas we found higher protein levels of this NADPH-oxidase component in both cytoplasmic and membrane fractions than in WKY aortas. Chronic quercetin treatment decreased the levels of this protein in both fractions of SHR aortas (Fig. 6b) .
Discussion
The underlying mechanisms involved in the improvement of endothelial function in hypertension by quercetin have not been analysed in detail. Herein, we show that the improved endothelial function in SHR chronically treated with quercetin was associated with enhanced eNOS activity and reduced expression of p47 phox and the subsequently reduced activity of NADPH oxidase.
In the rat aorta, endothelium-dependent vasodilatation relies almost entirely on the endothelial release of NO and the subsequent activation of soluble guanylate cyclase in vascular smooth muscle cells [18] . The endothelium-independent vasodilation induced by the soluble guanylate cyclase activator nitroprusside was similar in SHR and WKY and unaffected by quercetin, indicating that endothelial dysfunction and its improvement by quercetin are due to changes in endotheliumderived NO bioactivity, rather than downstream effects on vascular smooth muscle. Additionally, apparent changes in endothelium-dependent vasodilation may also occur as a consequence of the opposing effects of the release of endothelium-derived vasoconstrictors [19, 20] . In fact, consistent with previous reports [19] , SHR showed increased endothelium-dependent vasoconstriction induced by acetylcholine in arteries treated with the NO synthase inhibitor L-NAME. This response was abolished by the thromboxane-endoperoxide receptor antagonist SQ-29,548 [20] , indicating the involvement of endothelial release of vasoconstrictor prostanoids. However, in this model, quercetin did not modify the endothelium-dependent vasoconstriction induced by acetylcholine, suggesting that the protective effect of quercetin on endothelial function is unrelated to changes in endothelium-dependent vasoconstriction. These results do not rule out a possible effect of quercetin on endothelium-derived vasoconstriction in other rat models. In fact, acetylcholine-induced vasoconstriction was inhibited by chronic quercetin in NO-deficient [6] and in Goldblatt rats [9] . In addition, aortic TXA 2 production was increased in SHR (present study), in NOdeficient [6] and in Goldblatt rats [9] as compared to their normotensive controls. Again, quercetin reduced aortic TXA 2 levels in NO-deficient and in Goldblatt rats but not in SHR. In addition, quercetin, at relatively high doses, has been shown to reduce endothelial synthesis of endothelin-1 in vitro [21] . Taken together, these data strongly suggest that quercetin restores endothelial function in SHR by increasing NO bioactivity. Potential mechanisms whereby quercetin improves endotheliumderived NO responses may be related to: (1) changes in the activity and/or expression of eNOS; and (2) a decrease in vascular levels of O 2 À and, thus, reduced O 2 À -driven NO inactivation.
Reduced NO synthesis associated with endothelial dysfunction may be caused by several factors, such as impaired expression of eNOS, post-transductional modification of the enzyme (e.g. phosphorylation or fatty acid modifications), interactions with heat-shock protein 90 (hsp90) and caveolin, or suboptimal concentrations of the substrate L-arginine or the cofactor tetrahydrobiopterin (BH4) [22] . As previously reported [23] , the basal eNOS activity of SHR was significantly lower than that of WKY, which is consistent with decreased endothelium-dependent relaxation and higher blood pressure levels. Interestingly, quercetin enhanced eNOS activity in SHR, explaining, at least partly, the improvement of endothelium-dependent relaxation. This effect was not observed in WKY, suggesting that quercetin does not interfere with eNOS activity itself but rather with its expression, the abundance of cofactors, or other interacting proteins. The current data on the molecular regulation of vascular eNOS expression in SHR are rather conflicting; as both decreased [24] and increased eNOS protein expression [23, 25] compared to WKY have been reported. In the present study, in contrast to the reduced eNOS activity, aortic eNOS expression was increased and its inhibitory protein caveolin-1 was reduced in SHR as compared to WKY. This phenomenon is consistent with earlier studies, which demonstrated that NO exerts a negative feedback on regulation of eNOS expression [26] . The co-ordinated expressional changes in eNOS and its allosteric regulator, caveolin-1, may even be viewed as a compensatory mechanism to maintain the production of bioactive NO in the face of increased oxidant stress. In fact, we have shown that the enhancement of eNOS activity by quercetin prevents these compensatory expressional changes of eNOS and caveolin-1 protein in SHR.
Reduced O 2 À levels after chronic treatment with quercetin in experimental models of hypertension have been suggested, based on measurements of markers of systemic oxidative stress. Thus, urinary excretion of Quercetin and endothelial dysfunction Sá nchez et al. 81 isoprostane F 2a , plasma malondialdehyde, or plasma thiobarbituric acid reactive substances were reduced by quercetin in SHR [5, 27] , NO-deficient rats [6] , deoxycorticosterone acetate (DOCA)-salt treated rats [7, 28] or two-kidney, one-clip Goldblatt rats [9] . However, the effects of quercetin on vascular O 2 À production were unknown. In the present study we found that quercetin decreased vascular levels of O 2 À , which might be due to its ability to: (1) scavenge reactive oxygen species; (2) regulate enzymes that generate free radicals, such as NADPH oxidase; or (3) regulate antioxidant enzymes, including SODs, which metabolize free radicals.
Several studies have shown beneficial effects on blood pressure and endothelial function by treatment with antioxidants such as hydrosoluble coenzyme Q10 [29] or vitamins C and E [17] . The O 2 À -scavenging and antioxidant effects of quercetin and its glucuronized metabolites are well documented [1, [30] [31] [32] [33] . While this mechanism may contribute to improve endotheliumdependent relaxation in vivo, it is unlikely to play a role in the present ex vivo study because the experiments were performed 48 h after the final administration of quercetin, when plasma quercetin and its metabolites fall below 25% of the peak plasma levels [34] .
NADPH oxidase is a multi-subunit enzymatic complex responsible for the monoelectronic reduction of oxygen to produce O 2 À at the expense of NADPH [35] . Similarly to the neutrophil oxidase, vascular NADPH oxidase comprises a membrane-bound flavocytochrome b558 heterodimer [formed by gp91 phox (nox 2) or gp91 phox homologues (nox 1 and nox 4) and p22 phox ] and three cytoplasmic subunits, p47 phox , p67 phox and p40 phox [35] . This enzyme complex is considered to be the most important source of O 2 À in the vessel wall [36] . Excess of O 2 À generation synthesized by NADPH oxidase is critically involved in the breakdown of NO associated with endothelial dysfunction in experimental and clinical hypertension [12, 15, [37] [38] [39] [40] . We found that NADPHinduced generation of O 2 À was enhanced in SHR aortas and this effect was inhibited by quercetin. This result suggests that reduced NADPH oxidase-derived O 2 À , and thus reduced NO inactivation, may be an important mechanism contributing to the prevention of endothelial dysfunction by quercetin. Several recent studies have suggested a pivotal role of the p47 phox subunit of NADPH oxidase in the vascular oxidant stress and blood pressure response to angiotensin II in vivo [41, 42] . In fact, the NADPH oxidase inhibitor apocynin reduced blood pressure and endothelial dysfunction in angiotensin II-infused mice [38] and endothelial dysfunction in SHR in vitro (present study). In the present study, in SHR aortas we found higher protein levels of this NADPH-oxidase component in both the cytoplasmic and the membrane fractions than in WKY aortas. This increased p47 phox protein expression is consistent with the increased O 2 À production found in SHR aortas stimulated by NADPH. Quercetin treatment decreased the levels of this protein in both fractions of SHR aortas without a significant effect in WKY, suggesting that quercetin reduced NADPH-induced superoxide production by downregulating the expression of the p47 phox subunit of vascular NADPH oxidase.
The major conclusion to be drawn from this study is that oral treatment with the flavonoid quercetin resulted in an enhanced eNOS activity and a decreased NADPH oxidase mediated O 2 À generation associated with a reduced p47 phox expression. These findings provide novel evidence to aid understanding of how quercetin improves vascular endothelial function and lowers arterial blood pressure in hypertension, and further support the beneficial effects of this dietary factor in cardiovascular diseases associated with endothelial dysfunction, as suggested by epidemiological studies.
